MediWound (MDWD) said Wednesday it has initiated a global phase III trial evaluating EscharEx for the treatment of venous leg ulcers.
The trial will assess the efficacy and safety of EscharEx across 40 sites in the US and Europe, enrolling 216 patients in a randomized, double-blind study, focusing on complete debridement and wound closure, MediWound said.
Patients will undergo up to eight daily applications over two weeks, followed by ten weeks of wound management, the company said, adding that an interim analysis is planned for mid-2026 after 65% of patients have completed treatment.
To support the trial, MediWound said it has partnered with Solventum (SOLV), Molnlycke, and MiMedx Group (MDXG), who will supply advanced products to standardize wound management and enhance patient outcomes across all study sites.
MediWound also said it plans to start a phase II study comparing EscharEx to collagenase in VLU patients in 2025 and a phase II/III trial for diabetic foot ulcers in 2026.
MDWD shares were 1.7% higher in recent trading.
Price: 17.56, Change: +0.30, Percent Change: +1.74
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。